Compare Stocks: VIR, XENE, KNSA, and PTCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$78.47 -2.9%	$66.81	$32.89 ▼ $82.94	$6.30B	0.05	706,605 shs	546,866 shs
PTCT PTC Therapeutics	$70.52 -4.3%	$77.73	$48.27 ▼ $90.87	$6.15B	0.56	1.23 million shs	802,507 shs
VIR Vir Biotechnology	$9.21 -5.7%	$9.39	$4.25 ▼ $11.66	$1.65B	1.66	1.51 million shs	1.06 million shs
XENE Xenon Pharmaceuticals	$59.73 -4.2%	$62.15	$35.60 ▼ $72.66	$6.02B	0.62	624,692 shs	626,784 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	-2.88%	+0.82%	+23.48%	+47.39%	+136.28%
PTCT PTC Therapeutics	-4.28%	-2.01%	-10.17%	+2.49%	+44.36%
VIR Vir Biotechnology	-5.73%	+2.33%	-2.23%	+0.22%	+111.24%
XENE Xenon Pharmaceuticals	-4.16%	-7.01%	-10.50%	+10.26%	+58.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$78.47 -2.9%	$66.81	$32.89 ▼ $82.94	$6.30B	0.05	706,605 shs	546,866 shs
PTCT PTC Therapeutics	$70.52 -4.3%	$77.73	$48.27 ▼ $90.87	$6.15B	0.56	1.23 million shs	802,507 shs
VIR Vir Biotechnology	$9.21 -5.7%	$9.39	$4.25 ▼ $11.66	$1.65B	1.66	1.51 million shs	1.06 million shs
XENE Xenon Pharmaceuticals	$59.73 -4.2%	$62.15	$35.60 ▼ $72.66	$6.02B	0.62	624,692 shs	626,784 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	-2.88%	+0.82%	+23.48%	+47.39%	+136.28%
PTCT PTC Therapeutics	-4.28%	-2.01%	-10.17%	+2.49%	+44.36%
VIR Vir Biotechnology	-5.73%	+2.33%	-2.23%	+0.22%	+111.24%
XENE Xenon Pharmaceuticals	-4.16%	-7.01%	-10.50%	+10.26%	+58.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	11.35% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$98.55	39.74% Upside
VIR Vir Biotechnology	2.89	Moderate Buy	$20.63	123.94% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	29.14% Upside

Current Analyst Ratings Breakdown

Latest VIR, XENE, KNSA, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/13/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$106.00 ➝ $109.00
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$74.00
8/7/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$82.00 ➝ $81.00
8/6/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
8/6/2026	PTCT PTC Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/31/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $104.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KNSA Kiniksa Pharmaceuticals International	$677.56M	9.04	$0.77 per share	101.79	$8.38 per share	9.36
PTCT PTC Therapeutics	$1.73B	3.40	$8.41 per share	8.39	($1.98) per share	-35.62
VIR Vir Biotechnology	$68.56M	22.73	N/A	N/A	$5.81 per share	1.59
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	$12.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	80.90	37.91	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	33.11	2.27	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	11/4/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest VIR, XENE, KNSA, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
PTCT PTC Therapeutics	N/A	3.39	3.28
VIR Vir Biotechnology	N/A	6.04	6.04
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KNSA Kiniksa Pharmaceuticals International	53.95%
PTCT PTC Therapeutics	N/A
VIR Vir Biotechnology	65.32%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
KNSA Kiniksa Pharmaceuticals International	51.98%
PTCT PTC Therapeutics	5.30%
VIR Vir Biotechnology	2.90%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KNSA Kiniksa Pharmaceuticals International	220	78.02 million	37.47 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
VIR Vir Biotechnology	580	169.22 million	164.31 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

VIR, XENE, KNSA, and PTCT Headlines

Recent News About These Companies

Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

August 21 at 3:12 AM | marketbeat.com

Xenon Pharmaceuticals Inc

August 18 at 11:43 PM | money.usnews.com

TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE

August 18 at 5:44 AM | marketbeat.com

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

August 15, 2026 | marketbeat.com

Steven Gannon Sells 10,000 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

August 14, 2026 | insidertrades.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

August 14, 2026 | marketbeat.com

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock

August 13, 2026 | marketbeat.com

Q3 EPS Forecast for Xenon Pharmaceuticals Boosted by Analyst

August 13, 2026 | americanbankingnews.com

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity

August 11, 2026 | seekingalpha.com

HC Wainwright Issues Positive Outlook for XENE Earnings

August 11, 2026 | marketbeat.com

Equities Analysts Set Expectations for XENE Q1 Earnings

August 10, 2026 | americanbankingnews.com

Brokers Issue Forecasts for XENE Q1 Earnings

August 10, 2026 | marketbeat.com

Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

August 9, 2026 | marketbeat.com

Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

August 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

August 7, 2026 | zacks.com

California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE

August 7, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals Q2 Loss Widens

August 7, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VIR, XENE, KNSA, and PTCT Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$78.47 -2.33 (-2.88%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$78.46 -0.02 (-0.02%)

As of 08:09 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

PTC Therapeutics NASDAQ:PTCT

$70.52 -3.15 (-4.28%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$70.68 +0.16 (+0.22%)

As of 08:09 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Vir Biotechnology NASDAQ:VIR

$9.21 -0.56 (-5.73%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$9.38 +0.17 (+1.89%)

As of 08:23 AM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Xenon Pharmaceuticals NASDAQ:XENE

$59.73 -2.59 (-4.16%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$60.01 +0.28 (+0.47%)

As of 08:27 AM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIR, XENE, KNSA, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIR, XENE, KNSA, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIR, XENE, KNSA, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIR, XENE, KNSA, and PTCT Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

PTC Therapeutics NASDAQ:PTCT

Vir Biotechnology NASDAQ:VIR

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIR, XENE, KNSA, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIR, XENE, KNSA, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIR, XENE, KNSA, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIR, XENE, KNSA, and PTCT Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

PTC Therapeutics NASDAQ:PTCT

Vir Biotechnology NASDAQ:VIR

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools